Michael Severino, M.D., is leaving AbbVie and big pharma behind—but that’s not the end of the story. The leader is already entering his next chapter at Tessera Therapeutics, stepping into the world of biotech as CEO of the gene writing and rewriting company.

Roche is joining AstraZeneca, Bayer, Merck KGaA and more in a synthetic lethality race, paying Repare Therapeutics $125 million upfront for an ATR inhibitor with monotherapy and combination applications in indications such as ovarian cancer.

The FDA granted Sanofi’s hemophilia drug breakthrough status, as the French pharma continues pushing the therapy toward market as a potential rival to Roche’s blockbuster Hemlibra.

Sage Therapeutics and Biogen have delivered a clear win for zuranolone in the phase 3 SKYLARK trial of women with postpartum depression (PPD), although questions about the commercial opportunity led to a muted response to the data.

Bristol Myers Squibb will push its TYK2 inhibitor into phase 3 trials for lupus later this year off the back of positive midstage data as the drug awaits a key FDA decision for psoriasis.

Astellas has floored the accelerator on an immuno-oncology R&D project, putting down $20.5 million to team up with GO Therapeutics in a race to find antibodies with high affinity to two different glycoprotein targets.

Nearly two years after going live in Europe, the latest version of Abbott’s FreeStyle Libre continuous glucose monitor is ready to make its stateside debut.

Positive phase 3 trial results have maintained momentum for Axsome Therapeutics’ convoluted depression drug application, less than a month after the FDA rejected the company’s migraine treatment.

Minoryx has persuaded investors to overlook the failure of its phase 2/3 clinical trial, enabling it to reel in 51 million euros ($55 million) to support attempts to bring the rare disease drug to market in Europe and the U.S.

GSK is betting big to reenergize its fight for a share of the pneumococcal vaccine market, agreeing to pay $2.1 billion upfront to acquire Affinivax for a challenger to Pfizer’s blockbuster Prevnar franchise.